Seminars in Radiation Oncology
Volume 13, Issue 3 , Pages 322-332 , July 2003

Spinal cord and peripheral nerve injury: current management and investigations

  • William H St. Clair

      Affiliations

    • Department of Radiation Medicine, University of Kentucky, Lexington, KY USA
    • ,
  • Susanne M Arnold

      Affiliations

    • Division of Hematology and Oncology, University of Kentucky, Lexington, KY, USA
    • ,
  • Andrew E Sloan

      Affiliations

    • Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    • ,
  • William F Regine

      Affiliations

    • Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
    • Corresponding Author InformationAddress reprint requests to William F. Regine, MD, University of Maryland Medical Center, Department of Radiation Oncology, 22 South Greene Street, Room GGKO100, Baltimore, MD 21201-1595, USA

References 

  1. De Haas P, Kalkman CJ. Spinal cord monitoring (somatosensory- and motor-evoked potentials). Anaesthesiol Clin North Am. 2001;19:923–945
  2. Lipson AC, Gargollo PC, Black PM. Intraoperative magnetic resonance imaging (Considerations for the operating room of the future). J Clin Neurosci. 2001;8:305–310
  3. Jacobs WB, Perrin RG. Evaluation and treatment of spinal metastasis (an overview). Neurosurg Focus. 2001;11:1–11
  4. Sundaresan N, Krol G, Hughes JEO, et al.  Tumors of the spine (Diagnosis and management). In:  Tindall GT,  Cooper PR,  Barrow DL editor. The Practice of Neurosurgery. Baltimore, MD: Williams and Wilkins; 1996;
  5. Wiggens GC, Mirza S, Ballabarba C, et al.  Perioperative complications with costotransversectomy and anterior approaches to thoracic and thoracolumbar tumors. Neurosurg Focus. 2001;11:1–9
  6. Siegal T. Current Indications in the management of neoplastic spinal cord compression. Spine. 1989;14:223–228
  7. Turnbull IM, Breig A, Hassler O. Blood supply of the cervical spinal code in man. J Neurosurg. 1966;24:951–965
  8. Parke , Wesley W. Applied anatomy of the spine. In:  Horowitz HN,  Garfin SR,  Balderson RA, et al. editor. The Spine. Philadelphia, PA: Saunders; 1992;p. 35–88
  9. Heller JG. Complications of spinal surgery. In:  Horowitz HN,  Garfin SR,  Balderson RA, et al. editor. The Spine. Philadelphia, PA: Saunders; 1992;p. 1817–1836
  10. Hurlbert RJ, Moulton R. Why do you prescribe methylprednisolone for acute spinal cord injury? (A Canadian perspective and position statement). Can J Neurol Sci. 2002;29:236–239
  11. Wang X, Chun SJ, Treloar H, et al.  Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci. 2002;22:5505–5515
  12. McDonald JW, Becker D, Sadowsky CL, et al.  Late recovery following spinal cord Injury (Case report and review of the literature). J Neurosurg. 2002;97(suppl 2):252–265
  13. Crameri RM, Weston A, Climstein M, et al.  Effects of electrical stimulation induced training on skeletal muscle adaptability in spinal cord injury. Scand J Med Sci Sports. 2002;12:316–322
  14. Ishihara H, Kanamori M, Kawaguchi Y, et al.  Prediction of Neurologic outcome in patients with spinal cord injury by using hyperbaric oxygen therapy. J Orthop Sci. 2001;6:385–389
  15. Blesch A, Lu P, Tuszynski MH. Neurotrophic factors, gene therapy and neural stem cells for spinal cord repair. Brain Res Bull. 2002;57:833–838
  16. Lu J, Feron F, Mackay-Sim A, et al.  Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain. 2002;125:14–21
  17. Ramon-Cueto A, Santos-Benito FF. Cell therapy to repair injured spinal cords (Olfactory ensheathing glia transplantation). Restor Neurol Neurosci. 2001;19:149–156
  18. Woerly S, Doan VD, Evans-Martin F, et al.  Spinal cord reconstruction using NeuroGel implants and functional recovery after chronic injury. J Neurosci Res. 2001;66:1187–1197
  19. Friedman JA, Windebank AJ, Moor MJ, et al.  Biodegradable polymer grafts for surgical repair of the injured spinal cord. Neurosurgery. 2002;51:742–751
  20. Stolke D, Sollmann WP, Seifert V. Intra and post-operative complications in lumbar disk surgery. Spine. 1989;14:56–59
  21. Horwitz NH, Curtin JA. Prophylactic antibiotics and wound infections following laminectomy for lumbar disk herniation (A retrospective study). J Neurosurg. 1975;43:727–731
  22. Disa JJ, Smith AW, Bilsky MH. Management of radiated re-operative wounds of the cervicothoracic spine (The role of the trapezius turnover flap). Ann Plast Surg. 2001;47:394–397
  23. Yogev R. Cerebrospinal fluid inspectors (A personal view). Pediatr Infect Dis J. 1995;4:113–118
  24. Jones A. Transient radiation myelopathy (with reference to Lhermitte’s sign of electrical paraesthesia). Br J Radiol. 1964;37:727–744
  25. Thornton AF, Zimberg SH, Greenberg HS, et al.  Protracted Lhermitte’s sign following head and neck irradiation. Arch Otolaryngol Head Neck Surg. 1991;117:1300–1303
  26. Dynes JB, Smedal MI. Radiation myelitis. AJR Am J Roentgenol. 1960;83:78–87
  27. Leibel AA, Sheline GE. Tolerance of the brain and spinal cord to conventional irradiation. In:  Guhn PH,  Leibe SA,  Sheline GE editor. Radiation Injury to the Nervous System. New York, NY: Raven Press; 1991;
  28. Delatta JY, Rosenblum MK, Thaler HT, et al.  A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain. 1988;111:1319–1336
  29. Li Y, Jay V, Wang CS. Oligodendrocytes in the adult rate spinal cord undergo radiation-induced apoptosis. Cancer Res. 1996;56:5417–5422
  30. Walther PJ, Rossitch E, Bullard DE. The development of Lhermitte’s sign during cisplatin chemotherapy. Cancer. 1987;60:2170–2172
  31. Van den Bent M, Hilkens P, Smitt P, et al.  Lhermitte’s sign following chemotherapy with docetaxel. Neurology. 1998;50:563–564
  32. Dewar J, Lunt H, Abernathy DA, et al.  Cisplatin neuropathy with Lhermitte’s sign. J Neurol Neurosurg Psychiatry. 1986;49:96–99
  33. Kanchandani R, Howe JG. Lhermitte’s sign in multiple sclerosis (A clinical survey and review of the literature). J Neurol Neurosurg Psychiatry. 1982;45:308–312
  34. Butler WM, Taylor HG. Lhermitte’s sign in cobalamin (vitamin B12) deficiency. JAMA. 1981;245:1059–1060
  35. Schultheiss TE, Stephens LC, Peters LJ. Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys. 1986;12:1765–1769
  36. Rampling R, Symonds R. Radiation myelopathy. Curr Opin Neurol. 1998;11:627–632
  37. Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys. 1988;14:27–32
  38. van der Kogel AJ. Mechanisms of late radiation injury in the spinal cord. In:  Meyn RE,  Withers HR editor. Radiation Biology in Cancer Research. Philadelphia, PA: Raven Press Inc; 1980;p. 461–470
  39. Schultheiss TE. Spinal cord radiation “tolerance” (Doctrine versus date). Int J Radiat Oncol Biol Phys. 1990;19:219–221
  40. van der Kogel AJ. Dose-volume effects in the spinal cord. Radiother Oncol. 1993;29:105–109
  41. Yaes RJ, Kalend A. Local stem cell depletion model for radiation myelitis. Int J Radiat Oncol Biol Phys. 1988;14:1248–1259
  42. Hatlevoll R, Host H, Kaalhus O. Myelopathy following radiotherapy of bronchial carcinoma with large single fractions (A retrospective study). Int J Radiat Oncol Biol Phys. 1983;9:41–44
  43. Fitzgerald RH, Marks RD, Wallace KM. Chronic radiation myelitis. Radiology. 1982;144:609–612
  44. McCunniff AJ, Liang MJ. Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1989;16:675–678
  45. Marcus RB, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys. 1990;19:3–8
  46. van der Kogel AJ. Central nervous system radiation injury in small animal models. In:  Gutin PH,  Leibel SA,  Sheline GE editor. Radiation Injury To The Nervous System. Philadelphia, PA: Raven Press Inc; 1991;p. 91–111
  47. Ang KK, Price RE, Stephens LC, et al.  The tolerance of primate spinal cord to re-irradiation. Int J Radiat Oncol Biol Phys. 1993;25:459–464
  48. Schultheiss TE, Stevens LC. Radiation myelopathy. AJNR Am J Neuroradiol. 1992;13:1056–1058
  49. Hirota S, Soejima T, Higashino T, et al.  A case of chronic progressive chronic radiation myelitis treated with long-time corticosteroid administration. Jpn J Clin Radiol. 1998;43:649–652
  50. Glantz MJ, Burger PC, Friedman AH, et al.  Treatment of radiation induced nervous system injury with heparin and warfarin. Neurology. 1994;44:2020–2027
  51. Calabro F, Jinkins JR. MRI of radiation myelitis (A report of a case treated with hyperbaric oxygen). Eur Radiol. 2000;101:1079–1084
  52. Marin AC, Rierson B. Peripheral neuropathy secondary to cis-dichlorodiammino-platinum(II) (Platinol) (Treatment for advanced ovarian cancer). Ariz Med. 1979;36:898–899
  53. Mollman JE. Cisplatin neurotoxicity. N Engl J Med. 1990;2:126–127
  54. Greenspan A, Treat J. Peripheral neuropathy and low dose cisplatin. Am J Clin Oncol. 1988;11:660–662
  55. Wasserheit C, Frazein A, Oratz R, et al.  Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer (An active regimen with limiting neurotoxicity). J Clin Oncol. 1996;14:1993–1999
  56. Celik I, Kars A, Ozyar E, et al.  Major toxicity of cisplatin, fluorouracil, and leucovorin following chemoradiotherapy in patients with nasopharyngeal carcinoma. J Clin Oncol. 1996;14:1043–1044
  57. Grau JJ, Estape J, Cuchi MA, et al.  Calcium supplementation and ototoxicity in patients receiving cisplatin. Br J Clin Pharmacol. 1996;42:233–235
  58. Kovach JS, Moertel CG, Schutt AJ, et al.  Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep. 1973;57:357–359
  59. Melamed LB, Selim MA, Schuchman D. Cisplatin ototoxicity in gynecologic cancer patients (A preliminary report). Cancer. 1985;55:41–43
  60. Wilding G, Caruso R, Lawrence TS, et al.  Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3:1683–1689
  61. Alderson LM, Noonan PT, Choi IS, et al.  Regional subacute cranial neuropathies following internal carotid cisplatin infusion. Neurology. 1996;47:1088–1090
  62. Gore ME, Calvert AH, Smith LE. High dose carboplatin in the treatment of lung cancer and mesothelioma (A phase I dose escalation study). Eur J Cancer Clin Oncol. 1987;23:1391–1397
  63. Parsons SK, Neualt MW, Lehmann LE, et al.  Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998;22:669–674
  64. Extra JM, Marty M, Brienza S, et al.  Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25(suppl 5):13–22
  65. Culy CR, Clemett D, Wiseman LR. Oxaliplatin (A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies). Drugs. 2000;60:895–924
  66. Legha SS. Vincristine neurotoxicity (Pathophysiology and management). Med Toxicol. 1986;1:421–427
  67. Graf WD, Chance PF, Lensch MW, et al.  Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996;77:1356–1362
  68. Miller BR. Neurotoxicity and vincristine. JAMA. 1985;253:2045
  69. Lonardi F, Pavantato G, Ferrari V, et al.  Neurotoxicity after chemotherapy with vinorelbine. Eur J Cancer. 1993;29A:1794
  70. Pace A, Bove L, Nistico C, et al.  Vinorelbine neurotoxicity (clinical and neurophysiological findings in 23 patients). J Neurol Neurosurg Psychiatry. 1996;61:409–411
  71. Rowinsky EK, Cazenave LA, Donehower RC. Taxol (A novel investigational antimicrotubule agent). J Natl Cancer Inst. 1990;82:1247–1259
  72. Gordon AN, Stringer CA, Matthews CM, et al.  Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin (Rapid development of neurotoxicity is dose-limiting). J Clin Oncol. 1997;15:1965–1973
  73. New PZ, Jackson CE, Rinaldi D, et al.  Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology. 1996;46:108–111
  74. Faivre S, Kalla S, Cvitkovic E, et al.  Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma (An investigator-originated compassionate-use experience). Ann Oncol. 1999;10:1125–1128
  75. Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst. 1996;88:1079–1080
  76. Russell JA, Powles RL. Neuropathy due to cytosine arabinoside. Br Med J. 1974;4:652–653
  77. Borgeat A, DeMuralt B, Stalder M. Peripheral neuropathy associated with high-dose Ara-C therapy. Cancer. 1986;58:852–854
  78. Sarris AH, Hagemeister F, Romaguera J, et al.  Liposomal vincristine in relapsed non-Hodgkin’s lymphomas (Early results of an ongoing phase II trial). Ann Oncol. 2000;11:69–72
  79. Koeffler HP, Haskell CM. Rhabdomyolysis as a complication of 5-azacytidine. Cancer Treat Rep. 1978;62:573–574
  80. Cavaletti G, Sanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer. 2002;38:1832–1837
  81. Doolittle ND, Muldoon LL, Brummett RE, et al.  Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res. 2001;7:493–500
  82. Kemp G, Rose P, Lurain S, et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities (Results of a randomized control trial in patients with advanced ovarian cancer). J Clin Oncol. 1996;14:2101–2112
  83. Selvaggi G, Belani CP. Carboplatin and paclitaxel in non-small cell lung cancer (The role of amifostine). Semin Oncol. 1999;26(suppl 7):51–60
  84. Hensley ML, Schuchter LM, Lindley C, et al.  American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3355
  85. Vahdat L, Papadopoulos K, Lange D, et al.  Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001;7:1192–1197
  86. Cascinu S, Catalano V, Cordella L, et al.  Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer (A randomized, double-blind, placebo-controlled trial). J Clin Oncol. 2002;20:3478–3483
  87. van der Hoop GR, Vecht CJ, van der Burg MEL, et al.  Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990;322:89–94
  88. Roberts JA, Jenison EL, Kim K, et al.  A randomized, multi-center double-blind placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol. 1997;67:172–177
  89. Gao W-Q, Dybdal N, Shinsky N, et al.  Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol. 1995;38:30–37
  90. Apfel SC, Kessler JA, Adornato BT, et al.  Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology. 1998;51:695–702
  91. Maestri A, De Pasquale Ceratti A, Calandri C, et al.  Acetyl-L-carnitine (ALCAR) in patients with chemotherapy-induced peripheral sensory neuropathy. Proc Am Soc Clin Oncol. 2002;21:2476

PII: S1053-4296(03)00025-0

doi: 10.1016/S1053-4296(03)00025-0

Seminars in Radiation Oncology
Volume 13, Issue 3 , Pages 322-332 , July 2003

Article Tools